Jenburkt Pharmaceuticals Limited

BSE:524731 Stock Report

Market Cap: ₹5.2b

Jenburkt Pharmaceuticals Past Earnings Performance

Past criteria checks 5/6

Jenburkt Pharmaceuticals has been growing earnings at an average annual rate of 12.2%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 5% per year. Jenburkt Pharmaceuticals's return on equity is 19.2%, and it has net margins of 20.4%.

Key information

12.2%

Earnings growth rate

13.3%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate5.0%
Return on equity19.2%
Net Margin20.4%
Next Earnings Update28 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jenburkt Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524731 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,4833034510
30 Jun 241,4532804350
31 Mar 241,4202604250
31 Dec 231,3832444120
30 Sep 231,3722454010
30 Jun 231,3482403930
31 Mar 231,3672463880
31 Dec 221,2982173880
30 Sep 221,2832253800
30 Jun 221,2792363700
31 Mar 221,2402233650
31 Dec 211,2522273530
30 Sep 211,2412243410
30 Jun 211,1902013290
31 Mar 211,0931653240
31 Dec 201,1001723400
30 Sep 201,1181593460
30 Jun 201,1551583580
31 Mar 201,1891493650
31 Dec 191,2371713520
30 Sep 191,2241703410
30 Jun 191,2021723220
31 Mar 191,2261983120
31 Dec 181,1761852990
30 Sep 181,1621862900
30 Jun 181,2092282900
31 Mar 181,1471722790
31 Dec 171,1201512770
30 Sep 171,0601362730
30 Jun 17980862590
31 Mar 171,0331352520
31 Dec 169791122630
30 Sep 169721182520
30 Jun 169371022470
31 Mar 169361082410
31 Dec 159401174327
30 Sep 159111094277
30 Jun 158821071960
31 Mar 15852962030
31 Dec 14827973836
30 Sep 14809903776
30 Jun 14784811750
31 Mar 14762753716

Quality Earnings: 524731 has high quality earnings.

Growing Profit Margin: 524731's current net profit margins (20.4%) are higher than last year (17.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524731's earnings have grown by 12.2% per year over the past 5 years.

Accelerating Growth: 524731's earnings growth over the past year (23.8%) exceeds its 5-year average (12.2% per year).

Earnings vs Industry: 524731 earnings growth over the past year (23.8%) exceeded the Pharmaceuticals industry 20.6%.

Return on Equity

High ROE: 524731's Return on Equity (19.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 11:18
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jenburkt Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research